1. Home
  2. RNR vs MDGL Comparison

RNR vs MDGL Comparison

Compare RNR & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenaissanceRe Holdings Ltd.

RNR

RenaissanceRe Holdings Ltd.

HOLD

Current Price

$279.15

Market Cap

12.3B

Sector

Finance

ML Signal

HOLD

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$550.59

Market Cap

12.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNR
MDGL
Founded
1993
2011
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3B
12.5B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
RNR
MDGL
Price
$279.15
$550.59
Analyst Decision
Hold
Strong Buy
Analyst Count
14
14
Target Price
$296.83
$580.77
AVG Volume (30 Days)
374.5K
301.8K
Earning Date
01-27-2026
02-25-2026
Dividend Yield
0.58%
N/A
EPS Growth
N/A
N/A
EPS
34.70
N/A
Revenue
$12,214,870,000.00
$740,640,000.00
Revenue This Year
N/A
$435.63
Revenue Next Year
N/A
$52.56
P/E Ratio
$7.90
N/A
Revenue Growth
N/A
864.21
52 Week Low
$219.00
$265.00
52 Week High
$285.26
$615.00

Technical Indicators

Market Signals
Indicator
RNR
MDGL
Relative Strength Index (RSI) 57.64 43.01
Support Level $268.57 $532.45
Resistance Level $285.26 $589.98
Average True Range (ATR) 5.10 21.40
MACD -0.88 -6.38
Stochastic Oscillator 68.06 20.40

Price Performance

Historical Comparison
RNR
MDGL

About RNR RenaissanceRe Holdings Ltd.

RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: